Breaking News, Financial News

Financial Report: Abbott 3Q

Growth in the quarter was driven by worldwide pharmaceutical sales, up 22% to $4.9 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 3Q 3Q Revenues: $8.7 billion (+12%) 3Q Earnings: $891.0 million (-40%) YTD Revenues: $25.2 billion (+15%) YTD Earnings: $3.2 billion (-24%) Comments: Growth in the quarter was driven by worldwide pharmaceutical sales, up 22% to $4.9 billion. Humira sales were $1.7 billion in the quarter, up 13%. Trilipix/TriCor sales were $404 million (+22%). Niaspan sales were up 5% to $225 million. Kaletra sales were down 7% to $328 million and Lupron sales were down 3% to $189 million. W...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters